Photopheresis for recurrent acute rejection in cardiac transplantation

Giunti, Guido; Schürfeld, Karin; Maccherini, Massimo; Tanganelli, Piero; Rubegni, Pietro; Alfani, D; D'Ascenzo, G; Diciolla, Francesco; Bernazzali, Sonia; Fimiani, Michele; Toscano, Massimiliano; Sani, Guido

doi:10.1016/s0041-1345(98)01471-7

Cited by 26 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These rates were lower compared to the reported incidence with a similar regimen without ECP and pentostatin 18,27. The positive effects seen with ECP in the treatment of renal and cardiac allograft rejection10,11 lead to the evaluation of ECP in our study in order to prevent graft rejection or enhance engraftment.…”

Section: Discussionmentioning

confidence: 63%

Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment

Bethge

Kerbauy

Santos

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Extracorporeal photopheresis (ECP) and the purine analog pentostatin exert potent immunomodulatory effects but have not been evaluated for their ability to enhance engraftment of hematopoietic stem cells. We evaluated in a canine model of dog leukocyte antigen (DLA)-identical hematopoietic cell transplantation (HCT) whether ECP in combination with pentostatin could enhance engraftment using a nonmyeloablative regimen consisting of 100 cGy total body irradiation (TBI) and postgrafting immunosuppression with mycophenolate mofetil (MMF) and cyclosporine (CSP). We have shown previously that with 100 cGy TBI alone as conditioning, all of six dogs rejected their graft 2–12 weeks after HCT. With the addition of pentostatin to 100 cGy TBI, 6 of 10 dogs rejected their graft. We now tested the additional use of ECP alone (n=2) or ECP plus 3–6 doses of pentostatin (n=7) before 100 cGy TBI and HCT. Eight out of 9 dogs rejected their grafts within 6–11 weeks after HCT. Compared to data without ECP, we failed to demonstrate a positive impact of the use of either ECP or pentostatin for prevention of rejection.

show abstract

Section: Discussionmentioning

confidence: 63%

Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment

Bethge

Kerbauy

Santos

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Several case reports have been published demonstrating the beneficial effects of ECP on patients after cardiac transplantation; some use ECP as prophylaxis and others as treatment for acute rejection [83][84][85][86]. The first multicenter, randomized study using ECP for patients with acute rejection assessed contemporary standard triple immune suppression therapy ± ECP performed prophylactically in the first 6 months after cardiac transplantation [87].…”

Section: Solid Organ Transplantationmentioning

confidence: 99%

National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis

Ratcliffe

Dunbar

Adamski

et al. 2015

Transfusion Medicine Reviews

View full text Add to dashboard Cite

“…Moreover, the benefits of ECP have been demonstrated on patient survival and allograft function during multiple and/or refractory rejection [180,181]. Several reports showed a beneficial effect of ECP in the prevention of coronary allograft vasculopathy, a leading cause of death after heart transplantation [182][183][184].…”

Section: Solid Organ Transplant Rejectionmentioning

confidence: 99%